Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study
A M Layton, M Schaller, B Homey, M A Hofmann, A P Bewley, P Lehmann, C Nohlgård, D B Sarwer, N Kerrouche, Y M Ma, A M Layton, M Schaller, B Homey, M A Hofmann, A P Bewley, P Lehmann, C Nohlgård, D B Sarwer, N Kerrouche, Y M Ma
Abstract
Background: Facial redness contributes to impaired psychosocial functioning in rosacea patients and the only approved treatment for erythema is topical brimonidine gel 0.33%.
Objectives: To evaluate patient-reported outcomes, as well as efficacy and safety, in subjects with self-perceived severe erythema treated with brimonidine gel 0.33% compared to vehicle.
Methods: An 8-day multicenter, randomized study comparing once-daily brimonidine gel 0.33% with vehicle gel using a facial redness questionnaire, subject satisfaction questionnaire and a patient diary of facial redness control to assess patient-reported outcomes.
Results: Of the 92 included subjects with self-perceived severe erythema, very few were satisfied with their appearance at baseline (4.2% brimonidine group, 0 vehicle group). On Day 8, significantly more brimonidine group subjects were satisfied with their facial appearance compared to vehicle group (36.9% vs. 21.5%; P < 0.05), with the overall treatment effect (69.6% vs. 40.4%; P < 0.01), and with the improvement in their facial redness (67.4% vs. 33.3%; P < 0.001). More brimonidine group subjects were able to control their facial redness daily (e.g. 83.0% vs. 38.9% on Day 1). On Day 8, significantly more brimonidine group subjects than vehicle group had at least a one-grade improvement from baseline in the Clinician Erythema Assessment score (71.7% vs. 35.7%; P = 0.0011) and Patient Self-Assessment score (76.1% vs. 47.6%; P = 0.004). More subjects in the brimonidine group (29.2%) reported treatment-related adverse events than in the vehicle group (15.9%) but most were mild and transient.
Conclusions: Once-daily brimonidine gel 0.33% allowed patients to rapidly control their facial redness and significantly improved patient-reported outcomes in the treatment of persistent facial erythema of rosacea.
Trial registration: ClinicalTrials.gov NCT01885000.
© 2015 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Figures
References
- Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69(6 Suppl 1): S27–S35.
- Wilkin J, Dahl M, Detmar M et al Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584–587.
- Jansen T. Clinical presentations and classification of rosacea. Ann Dermatol Venereol 2011; 138(Suppl 3): S192–S200.
- Wilkin J, Dahl M, Detmar M et al Standard grading system for rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2004; 50: 907–912.
- Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality‐of‐life instrument for acne rosacea. J Am Acad Dermatol 2007; 57: 213–221.
- Aksoy B, Altaykan‐Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol 2010; 163: 719–725.
- Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol 2014; 71: 973–980.
- Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol 2004; 51: 592–599.
- Feldman SR, Huang WW, Huynh TT. Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease. J Manag Care Spec Pharm 2014; 20: 623–629.
- Del Rosso JQ, Thiboutot D, Gallo R et al Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 2013; 92: 277–284.
- Del Rosso JQ, Thiboutot D, Gallo R et al Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis 2014; 93: 134–138.
- Piwnica D, Rosignoli C, de Ménonville ST et al Vasoconstriction and anti‐inflammatory properties of the selective α‐adrenergic receptor agonist brimonidine. J Dermatol Sci 2014; 75: 49–54.
- Fowler J, Jarratt M, Moore A et al Once‐daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle‐controlled studies. Br J Dermatol 2012; 166: 633–641.
- Fowler J Jr, Jackson M, Moore A et al Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. J Drugs Dermatol 2013; 12: 650–656.
- Moore A, Kempers S, Murakawa G et al Long‐term safety and efficacy of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1‐year open‐label study. J Drugs Dermatol 2014; 13: 56–61.
- Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey‐Outpatient Department data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol 2005; 153: 1176–1181.
- Abram K, Silm H, Maaroos HI, Oona M. Subjective disease perception and symptoms of depression in relation to healthcare‐seeking behaviour in patients with rosacea. Acta Derm Venereol 2009; 89: 488–491.
- Fowler J, Tan J, Jackson JM et al Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema. J Eur Acad Dermatol Venereol 2015; 29: 474–481.
- Tanghetti EA, Jackson JM, Belasco KT et al Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol 2015; 14: 33–40.
Source: PubMed